StockData
Thermo Fisher Scientific Inc. logo

Thermo Fisher Scientific Inc. (TMO) KPIs and segments

TMONYSEMeasuring & Controlling Devices, NECFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 26, 2026Last filing: 10-Q on Oct 30, 2026Score 10/3028% above fair value
$686.79−4.54 (-0.66%)

Close on Nov 17, 2026Market cap $254.47BP/E 36.2Yield 0.25%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Thermo Fisher Scientific · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Thermo Fisher Scientific: 40 chỉ số vận hành, trong đó có Remaining Performance Obligations / Backlog, Current Contract Liabilities và Current Contract Assets, Net, lấy từ 164 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q4 2027
Q3 2027
Q2 2027
Q1 2027
Q4 2026
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Laboratory Products and Biopharma Services($M)
6,8636,6936,0366,3795,9705,9955,640
Life Sciences Solutions($M)
2,7192,8152,6362,9462,5882,4992,341
Analytical Instruments($M)
2,0021,8471,7162,2151,8931,7281,718
Specialty Diagnostics($M)
1,0981,2051,1421,2201,1741,1341,148
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)15
Product revenues($M)
6,7536,8236,2777,2466,4896,2495,980
Services($M)
5,3845,1714,7284,9694,6334,6054,384
Consumables($M)
4,8705,0734,7225,0264,6794,6064,354
Instruments($M)
1,8831,7501,5552,2211,8111,6441,626
North America($M)
6,2666,1495,7056,1095,6895,7225,513
Europe($M)
3,2013,3112,9573,3673,0052,8302,624
Asia-Pacific($M)
2,2402,1041,9702,2772,0131,9201,891
Other regions($M)
430430372462415383337
Laboratory Products and Biopharma Services($M)
25662338395645
Life Sciences Solutions($M)
213922781142
Analytical Instruments($M)
11741354104
Specialty Diagnostics($M)
-6035032
Laboratory Products and Biopharma Services($M)
1,067936778925868825731
Life Sciences Solutions($M)
1,0221,0419541,046968919834
Analytical Instruments($M)
538424355583429325399
Specialty Diagnostics($M)
341334313324321306304
Life Sciences Solutions($M)
1,7061,7351,6321,7581,6271,5741,486
Laboratory Products and Biopharma Services($M)
1,6831,5431,2791,4551,3621,3281,230
Analytical Instruments($M)
1,0499228401,076919826883
Specialty Diagnostics($M)
511506485503492494469
Product revenues($M)
3,4153,3613,0163,5243,1703,0102,855
Services($M)
1,7161,5211,4141,4871,4131,3981,380
Specialty Diagnostics($M)
-21-24-35-36-34-25-33
Analytical Instruments($M)
-25-17-36-49-18-13-44
Life Sciences Solutions($M)
-85-59-20-51-32-25-43
Laboratory Products and Biopharma Services($M)
-272-260-259-298-297-206-205
Laboratory Products and Biopharma Services($M)
7,4147,1526,9216,4856,7636,7116,467
Life Sciences Solutions($M)
3,5973,5083,4903,4463,5523,1423,018
Analytical Instruments($M)
3,2593,1873,1043,1703,1893,0702,986
Specialty Diagnostics($M)
1,1291,3231,3321,3231,3071,2951,298
Remaining performance obligations (RPO)($M)
29,87029,70029,41026,46025,04024,540
Remaining Performance Obligations / Backlog($M)2
29,70029,41027,92026,46025,04024,540
Reported RPO / Backlog ($B)($M)
29.729.427.926.525.024.5
Portion of RPO Expected to Be Recognized as Revenue within Next 12 Months(%)
52.0%52.0%52.0%53.0%54.0%54.0%
Current Contract Liabilities (Deferred Revenue / Customer Advances)($M)2
2,9182,9282,7102,8522,8052,866
Noncurrent Contract Liabilities($M)
1,0431,0341,1831,1591,1221,127
Quarterly Revenue Recognized from Beginning-of-Year Contract Liability Balances (Q1–Q3)($M)
7101,2904107301,360
Current Contract Assets, Net($M)1
1,6881,6841,6661,6201,4411,366
Noncurrent Contract Assets, Net($M)
011114
Consolidated Organic Revenue Growth(%)3
6.0%5.0%1.0%3.0%3.0%2.0%1.0%
Reported Revenue Growth(%)
9.0%10.0%6.0%7.0%5.0%3.0%0.0%
Impact of Acquisitions, Net of Divestitures(%)
3.0%5.0%3.0%2.0%1.0%0.0%0.0%
Impact of Currency Translation(%)
0.0%1.0%2.0%2.0%1.0%1.0%-1.0%
Organic Revenue Growth — Life Sciences Solutions(%)3
1.0%3.0%1.0%4.0%5.0%4.0%2.0%
Reported Revenue Growth — Life Sciences Solutions(%)
5.0%13.0%13.0%13.0%8.0%6.0%2.0%
Impact of Acquisitions — Life Sciences Solutions(%)
4.0%9.0%9.0%8.0%3.0%1.0%2.0%
Impact of Currency Translation — Life Sciences Solutions(%)
0.0%1.0%3.0%2.0%1.0%1.0%-1.0%
Organic Revenue Growth — Analytical Instruments(%)3
6.0%7.0%-2.0%0.0%4.0%-4.0%3.0%
Reported Revenue Growth — Analytical Instruments(%)
6.0%7.0%0.0%1.0%5.0%-3.0%2.0%
Impact of Acquisitions — Analytical Instruments(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Impact of Currency Translation — Analytical Instruments(%)
0.0%0.0%2.0%2.0%1.0%1.0%-1.0%
Organic Revenue Growth — Specialty Diagnostics(%)3
0.0%5.0%-3.0%3.0%2.0%0.0%4.0%
Reported Revenue Growth — Specialty Diagnostics(%)
-6.0%6.0%-1.0%5.0%4.0%2.0%3.0%
Impact of Acquisitions — Specialty Diagnostics(%)
-6.0%0.0%0.0%0.0%0.0%0.0%0.0%
Impact of Currency Translation — Specialty Diagnostics(%)
0.0%1.0%3.0%2.0%2.0%1.0%-1.0%
Organic Revenue Growth — Laboratory Products & Biopharma Services(%)3
10.0%5.0%4.0%5.0%3.0%3.0%-1.0%
Reported Revenue Growth — Laboratory Products & Biopharma Services(%)
15.0%12.0%7.0%7.0%4.0%4.0%-1.0%
Impact of Acquisitions — Laboratory Products & Biopharma Services(%)
6.0%6.0%1.0%0.0%0.0%0.0%0.0%
Impact of Currency Translation — Laboratory Products & Biopharma Services(%)
0.0%1.0%2.0%2.0%1.0%1.0%-1.0%
R&D as % of Manufacturing Revenue(%)
6.7%6.9%6.9%
Fiscal Calendar Selling Days Delta(ngày)
-4004100-1100-2
Consumables Revenue($M)2
5,0734,7225,0264,6794,6064,354
Cost of Product Revenues($M)
3,4623,2613,7223,3193,2393,125
Cost of Service Revenues($M)
3,6503,3143,4823,2203,2073,004
Life Sciences Solutions Segment (Total Segment Revenue)($M)4
2,7192,8152,6362,9462,5882,4992,341
Biosciences (Molecular Biology Reagents, Cell Culture & Protein)($M)
1,0609811,0781,0231,075993
Genetic Sciences (Gene Sequencing, qPCR & Genetic Analysis)($M)
703655794720679677
BioProduction (Single-Use Bioproduction Systems & Consumables)($M)
941893966817745671
Other / Intersegment Eliminations — Life Sciences Solutions Segment($M)
1121071092800
Analytical Instruments Segment (Total Segment Revenue)($M)3
2,0021,8471,7162,2151,8931,7281,718
Chromatography and Mass Spectrometry (Chromatography & Mass Spectrometry)($M)
821798962841784773
Electron Microscopy / Materials & Structural Analysis (Cryo-EM Electron Microscopy & Semiconductors)($M)
707633914732652659
Chemical Analysis (Industrial, Environmental & Pharmaceutical Chemical Analysis)($M)
318285339320292286
Specialty Diagnostics Segment (Total Segment Revenue)($M)5
1,0981,2051,1421,2201,1741,1341,148
Clinical Diagnostics (Clinical Diagnostics & Specialty Testing)($M)
290271293283276263
ImmunoDiagnostics (Phadia Allergy & Autoimmune Diagnostics)($M)
248230231230234217
Microbiology (Clinical Microbiology & Culture Media)($M)
166160172162159152
Transplant Diagnostics (One Lambda HLA Transplant Diagnostics)($M)
134121130125124113
Healthcare Market Channel (Fisher Healthcare Hospital Diagnostics Distribution Channel)($M)
442430463444407474
Laboratory Products and Biopharma Services Segment (Total Segment Revenue)($M)4
6,8636,6936,0366,3795,9705,9955,640
Pharma Services — Patheon CDMO (Contract Pharmaceutical Manufacturing & Sterile Fill-Finish)($M)
1,8931,7412,0191,7221,7941,607
Clinical Research — PPD CRO (Global Clinical Research & Trial Services)($M)
2,3962,1282,0012,0191,9551,939
Research and Safety Market Channel — Fisher Scientific (Laboratory Distribution Channel)($M)
2,0361,8271,9691,8611,8831,727
Laboratory Products (Basic Equipment, Ultra-Low Temperature Freezers & Laboratory Plastics)($M)
608569631594601582
North America Revenue($M)
6,1495,7056,1095,6895,7225,513
Segment Income — Life Sciences Solutions($M)10
1,0221,0419541,046968919834
Segment Income Margin — Life Sciences Solutions(%)
37.6%37.0%36.2%35.5%37.4%36.8%35.6%
Margin Expansion (percentage points) — Life Sciences Solutions(%)
0.2%0.2%0.6%-1.1%2.0%0.1%-1.2%
Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Life Sciences Solutions($M)
2,3552,2192,5182,1942,1151,954
Intersegment Revenues — Note 11 — Life Sciences Solutions($M)
460417428394385387
Segment Cost of Revenues — ASU 2023-07 — Life Sciences Solutions($M)
1,0801,0041,187961925855
Segment SG&A — ASU 2023-07 — Life Sciences Solutions($M)
500496506470467468
Segment R&D Expense — ASU 2023-07 — Life Sciences Solutions($M)
140131145136135139
Other Segment Items — Life Sciences Solutions($M)
545063535445
Segment Purchases of PP&E — Life Sciences Solutions($M)
592051322543
Segment Depreciation — Life Sciences Solutions($M)
697074625659
Segment Income — Analytical Instruments($M)10
538424355583429325399
Segment Income Margin — Analytical Instruments(%)
26.9%23.0%20.7%26.3%22.6%18.8%23.2%
Margin Expansion (percentage points) — Analytical Instruments(%)
4.3%4.2%-2.5%-4.2%-2.3%-5.8%-0.5%
Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Analytical Instruments($M)
1,7991,6672,1601,8471,6691,677
Intersegment Revenues — Note 11 — Analytical Instruments($M)
474956465841
Segment Cost of Revenues — ASU 2023-07 — Analytical Instruments($M)
9258761,137975902835
Segment SG&A — ASU 2023-07 — Analytical Instruments($M)
315313305307317313
Segment R&D Expense — ASU 2023-07 — Analytical Instruments($M)
140139147144145137
Other Segment Items — Analytical Instruments($M)
433443393933
Segment Purchases of PP&E — Analytical Instruments($M)
173649181344
Segment Depreciation — Analytical Instruments($M)
272628262624
Segment Income — Specialty Diagnostics($M)9
341334313324321306304
Segment Income Margin — Specialty Diagnostics(%)
31.0%27.7%27.4%26.6%27.4%27.0%26.5%
Margin Expansion (percentage points) — Specialty Diagnostics(%)
3.6%0.7%0.9%3.0%1.5%0.3%0.0%
Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Specialty Diagnostics($M)
1,1881,1241,2021,1541,1181,130
Intersegment Revenues — Note 11 — Specialty Diagnostics($M)
171818201618
Segment Cost of Revenues — ASU 2023-07 — Specialty Diagnostics($M)
699657717682640679
Segment SG&A — ASU 2023-07 — Specialty Diagnostics($M)
177177179175183171
Segment R&D Expense — ASU 2023-07 — Specialty Diagnostics($M)
454444424745
Segment Purchases of PP&E — Specialty Diagnostics($M)
243536342533
Segment Depreciation — Specialty Diagnostics($M)
202423232322
Segment Income — Laboratory Products & Biopharma Services($M)9
1,067936778925868825731
Segment Income Margin — Laboratory Products & Biopharma Services(%)
15.5%14.0%12.9%14.5%14.5%13.8%13.0%
Margin Expansion (percentage points) — Laboratory Products & Biopharma Services(%)
1.0%0.2%-0.1%0.5%1.0%0.9%0.0%
Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Laboratory Products & Biopharma Services($M)
6,6525,9956,3355,9275,9535,603
Intersegment Revenues — Note 11 — Laboratory Products & Biopharma Services($M)
414145434237
Segment Cost of Revenues — ASU 2023-07 — Laboratory Products & Biopharma Services($M)
5,1504,7574,8814,6224,6674,410
Segment SG&A — ASU 2023-07 — Laboratory Products & Biopharma Services($M)
677597619582595588
Segment R&D Expense — ASU 2023-07 — Laboratory Products & Biopharma Services($M)
271515141413
Segment Purchases of PP&E — Laboratory Products & Biopharma Services($M)
260259298297206205
Segment Depreciation — Laboratory Products & Biopharma Services($M)
216186165115152172
Total Segment Income (4 Segments)($M)4
2,7352,3992,8782,5872,3752,269
Total Segment AR + Inventory (4 Segments)($M)
113,174113,281110,343103,020101,23099,041
Unallocated Corporate Assets: Cash, PP&E, Goodwill, Intangibles($M)
98,00398,43495,91988,20987,01385,272
Unallocated Corporate CapEx($M)
902831232536
Unallocated Corporate Depreciation($M)
000000
Total Restructuring & Other Costs — Note 14($M)1
9849461358298
Accrued Restructuring Costs Balance($M)
726570857459
Adjusted Operating Income($M)14
2,9682,7352,3992,8782,5872,3752,269
Adjusted Operating Margin(%)
24.5%22.8%21.8%23.6%23.3%21.9%21.9%
GAAP Operating Margin(%)
18.6%17.4%16.9%18.5%17.4%16.9%16.6%
Adjusted Gross Margin $M($M)
5,2004,9704,4905,1044,6624,4874,319
Adjusted Gross Margin %(%)
42.8%41.4%40.8%41.8%41.9%41.3%41.7%
GAAP Gross Margin %(%)
42.3%40.7%40.3%41.0%41.2%40.6%40.9%
Amortization of Intangibles in COGS($M)
61614761686873
Adjusted SG&A Expense $M($M)
1,8831,8721,7551,8701,7291,7591,707
Adjusted SG&A % of Revenue(%)
15.5%15.6%16.0%15.3%15.5%16.2%16.5%
GAAP R&D % of Total Revenue(%)
2.9%3.0%3.1%2.9%3.1%3.2%3.3%
Adjusted EBITDA($M)
3,2763,0662,7053,1692,8132,6312,545
Adjusted Effective Tax Rate(%)
11.6%11.6%10.5%10.5%11.0%10.0%10.0%
Adjusted Net Income($M)
2,4772,2412,0272,4752,1902,0261,950
Adjusted Diluted EPS($)
6.686.035.446.575.795.365.15
Free Cash Flow = Operating Cash Flow − Net CapEx($M)
2,1151,6788253,0181,8401,105373
Adjusted ROIC — Trailing 5-Quarter Average(%)8
11.0%10.9%11.0%11.3%11.3%11.3%11.4%
TTM Adjusted NOPAT (12-Month)($M)
9,6629,3369,0568,963
Trailing 5-Quarter Average Invested Capital($M)
87,60985,42082,66979,313
Adjusted ROE(%)
18.3%18.0%17.7%17.7%17.7%17.5%17.9%
Trailing 5-Quarter Average Equity($M)
52,76751,90851,24350,765
Total Debt / TTM EBITDA(×)
3.603.804.003.703.503.403.30
Total Debt / Adjusted TTM EBITDA(×)
3.403.603.803.503.203.203.20
Net Debt / TTM EBITDA(×)
3.103.503.702.803.102.802.70
Net Debt / Adjusted TTM EBITDA(×)
2.903.303.502.602.902.702.60
Share Repurchases Total Spend($M)3
01,0003,00002,000
Shares Repurchased (million shares)(M)
02.104.902.1003.60
Remaining Share Repurchase Authorization($M)
1,0001,0002,0005,0001,0001,000
Dividends Paid per Share($)
0.470.470.430.430.39
Total Inventories — Note 2($M)3
5,6275,4965,4255,7455,5595,224
Raw Materials($M)
1,9911,9251,8771,9841,9471,862
Work in Process($M)
952942889990947874
Finished Goods($M)
2,6832,6292,6592,7712,6652,488
Property, Plant & Equipment, net — Note 2($M)
10,75510,65810,56510,1779,6359,331
FDA 510(k) Medical Device/Diagnostic Clearances Granted to Thermo Fisher (openFDA)3
1102364
Total FDA 510(k) Clearances for U.S. Medical Device & Diagnostic Industry (U.S. Industry Total)
855923756806797886736
FDA High-Risk Device PMA & Supplement Approvals Granted to Thermo Fisher (openFDA)
3129300
Total U.S. Industry FDA PMA & Supplements Approvals (U.S. Industry Total)
565608567525585588524
Thermo Fisher Medical Device Recalls Recorded in FDA CDRH System (openFDA Device Recalls)6
1612414
FDA Recall Enforcement Reports (Drugs + Devices + Biologics) for Thermo Fisher (openFDA Enforcement)
2512414
Total MAUDE MDR Device Adverse Event Reports for Thermo Fisher (openFDA MAUDE)
15131818121630
Device Malfunction MDRs — Thermo Fisher
33330115
Injury MDRs — Thermo Fisher
11101314111213
Death MDRs — Thermo Fisher
1021132
Total U.S. Industry MAUDE Device Adverse Event Reports (U.S. Industry Total MDRs)
1,189,467923,529811,618751,012819,444632,296685,251
U.S. Producer Price Index (PPI): Laboratory Analytical Instruments (NAICS 334516 — BLS/FRED)(×)5
203.60203.60202.00198.70195.80195.90194.50
U.S. Producer Price Index (PPI): In-Vitro Diagnostic Substances & Biologicals (NAICS 325413 — BLS/FRED)(×)
300.60300.60303.90300.50299.80297.70291.70
U.S. Producer Price Index (PPI): Pharmaceutical Preparation Manufacturing (NAICS 325412 — BLS/FRED)(×)
929.20926.20926.00919.30918.70914.90916.50
U.S. Producer Price Index (PPI): Medical Instruments & Equipment (NAICS 339112 — BLS/FRED)(×)
163.60163.40161.80159.80159.40157.10156.90
U.S. Producer Price Index (PPI): Electromedical Equipment (NAICS 334510 — BLS/FRED)(×)
92.8092.1092.0091.6090.9090.3090.10
U.S. Census QSS Hospitals Revenue ($M)($M)
47,89646,67446,83446,29545,37045,358
Consolidated Revenue($M)12
12,13711,99411,00512,21511,12210,85510,364
Gross Profit — Financial Statements & IR Reconciliation($M)
5,1314,8814,4305,0114,5844,4084,235
SG&A($M)
1,8632,3332,1812,3522,1622,1402,078
R&D Expense($M)
348364336356346352342
Restructuring & Merger Charges($M)
383436625643
Operating Income($M)
2,2632,0871,8632,2551,9411,8341,716
Interest Expense($M)
401354365347404303
Interest Income($M)
207233258234297203
Pretax Income($M)
1,9241,7342,1531,8261,7091,620
Income Tax Provision($M)
167701532079295
GAAP Net Income($M)
1,7211,7361,6511,9641,6161,6171,507
EPS pha loãng GAAP (GAAP Diluted EPS — DB & 8-K)($)
4.644.684.435.214.274.283.98
Dividends per Share($)
0.470.470.430.430.430.43
Total Assets($M)11
113,174113,281110,343103,020101,23099,041
Cash & Equivalents($M)
4,0643,2549,8521,9824,6034,172
Accounts Receivable, Net($M)
9,4519,2048,9008,9118,5948,455
Inventories, Net($M)
5,6275,4965,4255,7455,5595,224
PP&E, Net($M)
10,75510,65810,56510,1779,6359,331
Goodwill($M)
54,83255,18749,36249,28747,24946,493
Intangible Assets, Net($M)
18,60619,14615,83816,24215,14815,323
Accounts Payable($M)
3,2683,3443,6223,1202,9803,049
Current Deferred Revenue($M)
2,9182,9282,7102,8522,8052,866
Current Debt (Due Within 1 Year)($M)
3,3683,0903,5333,8232,2142,819
Long-Term Debt($M)
39,18140,07135,85231,85733,01531,370
Shareholders' Equity($M)
52,67951,93453,40751,01850,51249,390
Operating Cash Flow($M)5
2,1251,1923,4572,2391,399723
Capital Expenditures($M)
450376465404294362
Stock-Based Compensation($M)
828384708175
Acquisitions, Net of Cash Acquired($M)
-08,872-04,037-0-0
Share Repurchases($M)
1,0003,00037963-02,000
Dividends Paid($M)
175162162163162149

10 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Remaining Performance Obligations / Backlog from Note 2 of the 10-K/10-Q ($27.92 billion at the end of FY2025, $25.73 billion as of Q2 2026, with the % expected to be recognized as revenue over the next 12 months) and customer contract asset / liability balances.
  • Permissible quarterly derivations: Flow metrics reported only for Q1–Q3 and cumulative 6M/9M on Form 10-Q along with full-year figures on Form 10-K (15 sub-segments in Note 6, Consumables/Instruments/Services breakdown, 4 geographic regions, segment Cost of Goods Sold/SG&A/R&D expenses under ASU 2023-07 Note 11, restructuring charges in Note 14, and cash flows) have fourth-quarter figures derived using the formula Q4 = Full Year (10-K) − 9 Months (10-Q) from the same filing version.
  • Consolidated vs. standalone: Not applicable to TMO because the company prepares consolidated financial statements under US GAAP and does not issue standalone parent company financial statements (Schedule I is not required since restricted assets of subsidiaries are < 25% of consolidated assets).
  • Reporting cycle Q3 2026 vs. Q2 2026: The Q3 2026 8-K filing, Q3 2026 IR financial reconciliation package, Q3 2026 earnings call, openFDA, and BLS/FRED reflect data through FY2026Q3 (2026-09); detailed footnote disclosures available only in Form 10-Q (Note 2 RPO, Note 6 15 sub-segments, Note 11 ASU 2023-07 segment expenses) reflect data through FY2026Q2 because the Q3 2026 10-Q was not yet filed at the time of the Q3 2026 8-K earnings release.

Không hiện vì thiếu các kỳ gần đây (11)

  • Total Restructuring & Other Costs — Note 14 › Restructuring Costs — Specialty Diagnostics
  • Total Restructuring & Other Costs — Note 14 › Restructuring Costs — Corporate
  • Consolidated Revenue › Cost of Revenue (discontinued after FY2018 when Product/Service separated)
  • Consolidated Revenue › Diluted Shares
  • Operating Cash Flow › Depreciation & Amortization
  • China Revenue (no longer reported separately in Note 11 after Q2 2023)
  • Germany Revenue (no longer reported separately after FY2016)
  • UK Revenue (discontinued as a separate disclosure after FY2016)
  • Japan Revenue (discontinued as a separate disclosure after FY2016)
  • Adjusted ROIC — Trailing 5-Quarter Average › GAAP-based ROIC
  • Share Repurchases Total Spend › Average Price Paid per Share

Dữ liệu cập nhật 2026-10-29.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

8. Financial Statement & Cash Flow Context from Financial Statements

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Thermo Fisher Scientific

See a number that looks wrong?